biotech · Respiratory Distress Syndrome · Cardiogenic Shock · WINT
WINDTREE THERAPEUTICS INC
WINDTREE THERAPEUTICS INC /DE/
WINDTREE THERAPEUTICS INC patent portfolio — 4 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 2600 Kelly Rd., Suite 100, Warrington, PA 18976, US
- Founded
- 1992
- Employees
- 17
- Programs
- 15
- Drugs
- 9
- Patents
- 4
WINDTREE THERAPEUTICS INC patents
4 pharmaceutical patents indexed for WINDTREE THERAPEUTICS INC. 0 expire within 24 months.
WINDTREE THERAPEUTICS INC has 4 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12343350
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 11583540
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 11197869
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
granted -
US 9554999
Lyophilization of synthetic liposomal pulmonary surfactant
granted
Frequently asked questions
How many patents does WINDTREE THERAPEUTICS INC have?
4 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do WINDTREE THERAPEUTICS INC patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.